Drugs / OPN-019
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05035576 Comparator | Sep → Nov 2021 | COVID-19 | Optinose US Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPN-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035576 ↗ |
| Route | Intranasal | “2 sprays per nostril” NCT05035576 ↗ |